New clinical trial offers hope for patients with rare immune disease IgG4-RD

A team led by Mass General Brigham researchers demonstrated that inebilizumab reduced the risk of symptoms by 87% in patients with the rare affliction known as immunoglobulin G4–related disease (IgG4-RD)

Silicone wristbands track personal PAH exposure

Environmental epidemiologists at Columbia University Mailman School of Public Health, in collaboration with an interdisciplinary team of researchers at Oregon State University, Pacific Northwest National

January 11, 2024

More Evidence Favors a Shorter Course of Post-Mastectomy RT

Hypofractionated post-mastectomy radiation therapy (RT) with breast reconstruction proved noninferior to standard RT when it came to reconstruction complications, high-grade toxicity, and local control, according

October 2, 2024

Evotec SE reports results for the first nine months 2023 and provides corporate update – Biotech Investments

EQS-News: Evotec SE / Key word(s): 9 Month figures Evotec SE reports results for the first nine months 2023 and provides corporate update 08.11.2023 /

November 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.